GlassScriptPhysician profile
Terry C Chambless
NPI 1831188572
$2,741.78
in general payments reported to CMS, 2019-2025
24 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $319 · 2021: $259 · 2022: $382 · 2023: $459 · 2024: $524 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,398.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,322.78 | 2020-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $217.13 | 2019-2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $204.60 | 2019-2024 | Trintellix |
| Pfizer INC. | $133.73 | 2019-2025 | |
| Glaxosmithkline, LLC. | $131.76 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $122.01 | 2020-2024 | Farxiga, Airsupra |
| Amarin Pharma, INC. | $102.30 | 2019-2021 | |
| Lilly USA, LLC | $73.07 | 2019-2024 | Mounjaro, Zepbound, Emgality |
| Novartis Pharmaceuticals Corporation | $53.76 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $51.72 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $49.16 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $47.92 | 2022 | |
| Esperion Therapeutics, INC. | $30.87 | 2021 | |
| Allergan, INC. | $30.42 | 2019-2020 | |
| Antares Pharma, INC. | $26.39 | 2020-2023 | Tlando, Xyosted, Nocdurna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24.15 | 2021 | |
| Tolmar, INC. | $22.97 | 2023 | |
| Idorsia Pharmaceuticals US INC | $18.43 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $15.65 | 2024 | Auvelity |
| Genentech USA, INC. | $14.65 | 2019 | |
| Ibsa Pharma INC. | $13.60 | 2022 | |
| Corium, LLC | $12.71 | 2023 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.15 | 2020 | |
| Mannkind Corporation | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Chambless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.